

Special Issue

The Development and Severity of Infectious Uveitis

Message from the Guest Editors

Infections are a leading cause of ocular inflammation worldwide. By exogenous or endogenous transmission, a wide variety of pathogens including bacteria, viruses, fungi, and parasites can cause infectious uveitis. While certain entities such as toxoplasmosis, syphilis, and tuberculosis comprise the majority of cases of intraocular inflammation, other emerging pathogens have also been shown to cause uveitis. The development of infectious uveitis can range from rapidly progressive fulminant infection to a chronic, indolent course. Diagnosis of intraocular infections can be challenging and multiple factors may lead to significant ocular morbidity including delay in diagnosis, drug-resistant infections, and concomitant inflammation, which can destroy ocular tissues. This Special Issue seeks manuscripts on the pathogenesis, severity, diagnosis, and management of infectious uveitis with a special focus on clinical presentation and management challenges, new diagnostic testing modalities, and antimicrobial drug delivery options.

Guest Editors

Dr. Ann Marie Lobo
Dr. Pooja Bhat
Dr. Tejabharam Yadavalli

Deadline for manuscript submissions

closed (31 January 2022)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 10.2
Indexed in PubMed



mdpi.com/si/81998

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 10.2
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)